Vir Biotechnology, Inc. (VIR)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 3
Buy limit 11.80 at EMA21 support (11.76) - a trend-aligned pullback with price above SMA50 11.18 and SMA200 9.75 and MACD 0.49 > 0; no earnings or dividend event through the 15-day horizon 2026-12-04. Structural swingLow 11.30 minus buffer 0.16 = 11.14, widened by the pullback ATR floor to 11.00 (1.0xATR); targets 13.40 (entry + 2.0xATR) and 14.60 (entry + 3.5xATR); R/R 2.00.
Company overview
Vir Biotechnology, Inc. is an immunology company focused on developing therapeutic solutions for infectious diseases. Its pipeline includes candidates for SARS-CoV-2, hepatitis B, influenza A, and HIV. The company collaborates with various organizations and maintains strategic partnerships to advance its research and development efforts.
Fundamental
fairVir Biotechnology has a strong balance sheet but lacks recurring revenue, making it a speculative, catalyst-driven company.
Mixed fundamentals: effectively no recurring revenue and heavy cash burn, offset by zero financial debt, roughly $900M of cash and investments, and a newly reported positive pivotal Phase 3 win in hepatitis delta. Balance-sheet strength and the clinical catalyst are real, but a binary single-asset outcome, rapid dilution and an absent earnings base keep this a speculative, catalyst-driven profile rather than a fundamentally anchored one.
Sentiment
fairSentiment is mixed, with recent trial success offset by earnings misses and no immediate catalysts.
Dominant catalyst is the announced 2026-11-09 pivotal Phase 3 ECLIPSE 1 win for elebsiran/tobevibart in chronic hepatitis delta (44% vs 0% virologic response, all endpoints met), which the tape rewarded with a ~22% single-session move and a follow-on price-target cluster at $17–$23, set against a 2026-11-04 Q3 revenue miss and per-share loss that in-window coverage scored negative. The 14-day media read is mixed at a polarity score of roughly +0.17 against a baseline of roughly +0.13 (delta flat); the severe red-flag screen is clean, but a moderate conflicting-catalysts flag fires because both the bullish Phase 3 leg and the bearish earnings leg sit inside the actionable window on a complete array — moderate red-flag cap applied, with the anchoring catalyst already two days old and partially priced and no scheduled driver inside 30 trading days.
Technical
fairThe stock is in a pullback within an intact uptrend, with support levels offering a favorable risk-reward setup.
Mixed-to-constructive: the medium-term trend is intact (price 12.12 above SMA20 11.47, SMA50 11.18, SMA200 9.75 and EMA21 11.76, ADX14 25.56 rising, MACD 0.49/0.34/0.15 still positive), but the short-term tape weakened after a 16% two-day pullback from 14.38 (close below EMA9 12.29 and VWAP 12.37, RSI cooled 68.3 to 54.0, MACD histogram contracted 0.23 to 0.15, -6.4% distribution day closing near the low). Because price sits above the SMA50 with MACD > 0 the dip is trend-aligned, not countertrend, so a pullback limit at EMA21 support with a structure-based stop yields an acceptable 2.00 R/R and a score of 3 supports the trade.
You’re looking at 2026-11-12 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

